Table 2. Participants with positive-HRCT findings in EGPA and in severe asthma.
| HRCT findings | EGPA (n=96), n [%] | Severe asthma (n=82), n [%] | P value |
|---|---|---|---|
| Airway signs | |||
| Bronchial wall thickening | 93 [97] | 69 [84] | 0.003 |
| Air trapping | 58/59 [98]* | 42/52 [81]# | 0.002 |
| Tree-in-bud opacities | 60 [63] | 12 [15] | <0.001 |
| Bronchial mucoid impaction | 49 [51] | 10 [12] | <0.001 |
| Bronchiectasis | 38 [40] | 5 [6] | <0.001 |
| Mosaic perfusion | 9 [9] | 3 [4] | 0.129 |
| Airspace signs | |||
| Diffused GGOs | 71 [74] | 15 [18] | <0.001 |
| Consolidation | 37 [39] | 17 [21] | 0.010 |
| Single GGO | 15 [16] | 23 [28] | 0.044 |
| Other signs | |||
| Increased small vascular markings | 44 [46] | 2 [2] | <0.001 |
| Emphysema | 35 [36] | 17 [21] | 0.021 |
| Mediastinal or hilar lymphadenopathy | 22 [23] | 11 [13] | 0.074 |
| Interlobular septal thickening | 18 [19] | 2 [3] | 0.001 |
| Atelectasis | 11 [11] | 1 [1] | 0.007 |
Data are presented as n (%). *, 59 of the EGPA participants underwent HRCT scans at both inspiration and expiration phases. #, 52 participants with severe asthma underwent HRCT scans at both inspiration and expiration phases. HRCT, high-resolution computed tomography; EGPA, eosinophilic granulomatosis with polyangiitis; GGO, ground-glass opacity.